Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults: Mayo Clinic Study of Aging.
Kelly D Flemming, Jonathan Graff-Radford, Jeremiah Aakre...
https://pubmed.ncbi.nlm.nih.gov/28492932/Actively Recruiting
Led by Huashan Hospital · Updated on 2024-12-20
75
Participants Needed
2
Research Sites
52 weeks
Total Duration
Researchers are evaluating sirolimus, a drug approved by the FDA and used for certain malformations, to see if it is safe and tolerable in reducing brain hemorrhages in people with brainstem cavernous malformations BSCMs. This pilot phase 2 clinical trial compares sirolimus to a placebo to inform a future larger study. The focus is on preventing intracerebral hemorrhage ICH during high-risk periods for rebleeding in adults aged 18 to 65. Participants are randomly assigned to one of three groups high-dose sirolimus targeting blood levels of 9-15 ngml, low-dose sirolimus targeting 3-7 ngml, or a placebo made of starch. Treatments are taken orally and continued continuously for 12 months. The study is blinded so that neither participants nor researchers know the assigned group. During the 24-month follow-up, researchers will monitor safety and tolerability of sirolimus, track recurrent brain hemorrhages, assess brain scans using MRI, and evaluate participants quality of life. Participants will undergo regular assessments including imaging and clinical evaluations to measure these outcomes. The study aims to gather important data on sirolimus treatment effects and safety over two years.
CONDITIONS
Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial
Z
Zongze Li, Doctor
W
Wei Zhu, Doctor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Huashan Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants receive oral sirolimus or placebo continuously as assigned to manage brainstem cavernous malformations.
Regular visits for monitoring during treatment
Duration - 12 months
Participants are monitored for safety, tolerability, and efficacy outcomes after treatment.
Periodic visits up to 24 months from randomization
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Kelly D Flemming, Jonathan Graff-Radford, Jeremiah Aakre...
https://pubmed.ncbi.nlm.nih.gov/28492932/Cong Yan, Yongqing Ye, Nan Liu...
https://pubmed.ncbi.nlm.nih.gov/40570636/Aileen A Ren, Daniel A Snellings, Yourong S Su...
https://pubmed.ncbi.nlm.nih.gov/33910229/Jian Ren, Yazi Huang, Yeqing Ren...
https://pubmed.ncbi.nlm.nih.gov/36995941/Huashan Hospital
Lead Sponsor